Presentation is loading. Please wait.

Presentation is loading. Please wait.

Immune response of CEA-transgenic mice transferred with OT-1 splenocytes and immunized with ovalbumin and adjuvant. Immune response of CEA-transgenic mice.

Published by刀斐 钮 Modified over 5 years ago

Similar presentations

Presentation on theme: "Immune response of CEA-transgenic mice transferred with OT-1 splenocytes and immunized with ovalbumin and adjuvant. Immune response of CEA-transgenic mice."— Presentation transcript:

1 Immune response of CEA-transgenic mice transferred with OT-1 splenocytes and immunized with ovalbumin and adjuvant. Immune response of CEA-transgenic mice transferred with OT-1 splenocytes and immunized with ovalbumin and adjuvant. (A) Kinetics of the immune response to ova peptide followed by double-color fluorescence staining with anti-CD8 FITC and H-2Kb/ova tetramer-PE. As indicated by the arrow, tumor grafting was performed 19 days after immunization. Results are expressed as the percentage of specific H-2Kb/ova over total CD8 T cells. (B) Representative FACS dot blot at the peak of response 11 days after injection. Alena Donda et al. Cancer Immun 2003;3:11 Copyright © 2003 by Jean-Pierre Mach

Download ppt "Immune response of CEA-transgenic mice transferred with OT-1 splenocytes and immunized with ovalbumin and adjuvant. Immune response of CEA-transgenic mice."

Similar presentations

Life and Death of CD8 T Cells: A Role of IL-12

Life and Death of CD8 T Cells: A Role of IL-12
Figure 2. Positive selection of J15 TCR transgenic T cells specific for H60. (A) CD4 by CD8 profiles (left) of thymocytes and numbers (right) of each thymic.

Figure 2. Positive selection of J15 TCR transgenic T cells specific for H60. (A) CD4 by CD8 profiles (left) of thymocytes and numbers (right) of each thymic.
Fig. 1. Level of Mac-1 expression on naive and recently activated LCMV GP33–41-specific T cells from TCR 318 transgenic mice. (A and B) Splenocytes from.

Fig. 1. Level of Mac-1 expression on naive and recently activated LCMV GP33–41-specific T cells from TCR 318 transgenic mice. (A and B) Splenocytes from.
Selinexor combines with immune checkpoint blockade to slow B16F10 melanoma tumor growth. Selinexor combines with immune checkpoint blockade to slow B16F10.

Selinexor combines with immune checkpoint blockade to slow B16F10 melanoma tumor growth. Selinexor combines with immune checkpoint blockade to slow B16F10.
Anti-CD40 and CpG induce activation of T cells in draining lymph nodes

Anti-CD40 and CpG induce activation of T cells in draining lymph nodes
Identification of CD3+CD4−CD8− T Cells as Potential Regulatory Cells in an Experimental Murine Model of Graft-Versus-Host Skin Disease (GVHD)  Fumi Miyagawa,

Identification of CD3+CD4−CD8− T Cells as Potential Regulatory Cells in an Experimental Murine Model of Graft-Versus-Host Skin Disease (GVHD)  Fumi Miyagawa,
Detection of CD38+IgG1+ memory B cells adjacent to contracted GCs

Detection of CD38+IgG1+ memory B cells adjacent to contracted GCs
Cognate interaction with antigen-specific T cells is required for the response of IgG-type memory B cells. Cognate interaction with antigen-specific T.

Cognate interaction with antigen-specific T cells is required for the response of IgG-type memory B cells. Cognate interaction with antigen-specific T.
Interaction between B7-H1 and PD-1 determines initiation and reversal of T-cell anergy by Fumihiko Tsushima, Sheng Yao, Tahiro Shin, Andrew Flies, Sarah.

Interaction between B7-H1 and PD-1 determines initiation and reversal of T-cell anergy by Fumihiko Tsushima, Sheng Yao, Tahiro Shin, Andrew Flies, Sarah.
Simple conditioning with monospecific CD4+CD25+ regulatory T cells for bone marrow engraftment and tolerance to multiple gene products by David-Alexandre.

Simple conditioning with monospecific CD4+CD25+ regulatory T cells for bone marrow engraftment and tolerance to multiple gene products by David-Alexandre.
Volume 25, Issue 11, Pages (November 2017)

Volume 25, Issue 11, Pages (November 2017)
Γδ T Cells Augment Rejection of Skin Grafts by Enhancing Cross-Priming of CD8 T Cells to Skin-Derived Antigen  Azad Rahimpour, Stephen R. Mattarollo,

Γδ T Cells Augment Rejection of Skin Grafts by Enhancing Cross-Priming of CD8 T Cells to Skin-Derived Antigen  Azad Rahimpour, Stephen R. Mattarollo,
Loss of Runx2 in the T cell compartment leads to a defect in the number of CD8+ memory precursor T cells during LCMV–Armstrong infection. Loss of Runx2.

Loss of Runx2 in the T cell compartment leads to a defect in the number of CD8+ memory precursor T cells during LCMV–Armstrong infection. Loss of Runx2.
IL-6 is dispensable for the suppressive activity of MDSC on primary CD4+ T-cell activation. IL-6 is dispensable for the suppressive activity of MDSC on.

IL-6 is dispensable for the suppressive activity of MDSC on primary CD4+ T-cell activation. IL-6 is dispensable for the suppressive activity of MDSC on.
LV DNA, genome, and capsid are not required for DC activation and CD8+ T cell priming in vivo. LV DNA, genome, and capsid are not required for DC activation.

LV DNA, genome, and capsid are not required for DC activation and CD8+ T cell priming in vivo. LV DNA, genome, and capsid are not required for DC activation.
Gr-1+ MDSC in tumor-bearing mice produce IL-6.

Gr-1+ MDSC in tumor-bearing mice produce IL-6.
Volume 31, Issue 1, Pages (July 2009)

Volume 31, Issue 1, Pages (July 2009)
Activating anti-CD40 antibody partially mitigates the deficit in CTL generation and accumulation elicited by immunization with F/T 4T1-OVA cells. Activating.

Activating anti-CD40 antibody partially mitigates the deficit in CTL generation and accumulation elicited by immunization with F/T 4T1-OVA cells. Activating.
VLPs activate DCs and antigen-specific CD8+ T cells via the STING and cGAS pathway. VLPs activate DCs and antigen-specific CD8+ T cells via the STING and.

VLPs activate DCs and antigen-specific CD8+ T cells via the STING and cGAS pathway. VLPs activate DCs and antigen-specific CD8+ T cells via the STING and.
Volume 18, Issue 3, Pages (March 2003)

Volume 18, Issue 3, Pages (March 2003)

Similar presentations

Ads by Google